IGC Pharma Inc IGC

Healthcare Cannabis

IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aß plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aß plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aß plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.

NYSEAM:IGC - Post by User

IGC Pharma Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Aug 20, 2024 6:18pm

28 Views

Post# 36188850

IGC Pharma Expands Drug Portfolio to Metabolic Disorders wit

NEWS: $IGC IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist- Artificial Intelligence Modelling Reveals New Possibilities for Metabolic and Neurological Therapies - IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") today announced that the Company's proprietary molecule, IGC-1A, has been identified as a potential GLP-1 agon...IGC - IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist

<< Previous

Bullboard Posts

Next >>

AI companies to invest in